BACKGROUND: Delivering a non-pharmacological symptom management intervention in patients with lung cancer is often challenging due to difficulties with recruitment, high attrition rates, high symptom burden, and other methodological problems. The aim of the present study was to elicit quantitative estimates of utility (benefit) associated with different attribute levels (delivery options) of a symptom management intervention in lung cancer patients. METHODS: An application of Best-Worst scaling methodology was used. Effects (attributes) tested included the location of the intervention (home or hospital), type of trainer (health professional or trained volunteer), caregiver involvement or not, and intervention delivered individually or in groups of patients. Participants were asked to evaluate and compare their preferences (utilities) towards the different attribute levels within scenarios and select the pair of attribute levels that they consider to be furthest apart. RESULTS: Eighty-seven patients with lung cancer participated. The most important preferences for an intervention included the location (being delivered at home) and delivered by a health care professional. The least important preference was the involvement of a caregiver. Gender had an effect on preferences, with females being less inclined than men to prefer to receive an intervention in the home than the hospital and less inclined than men to have no other patients present. Furthermore, older participants and those in advanced stages of their disease were less inclined to have no other patients present compared to younger participants and those with earlier stages of disease, respectively. CONCLUSION: Considering patient preferences is an important step in developing feasible, patient-centred, appropriate and methodologically rigorous interventions and this study provided indications of such patient preferences.
BACKGROUND: Delivering a non-pharmacological symptom management intervention in patients with lung cancer is often challenging due to difficulties with recruitment, high attrition rates, high symptom burden, and other methodological problems. The aim of the present study was to elicit quantitative estimates of utility (benefit) associated with different attribute levels (delivery options) of a symptom management intervention in lung cancer patients. METHODS: An application of Best-Worst scaling methodology was used. Effects (attributes) tested included the location of the intervention (home or hospital), type of trainer (health professional or trained volunteer), caregiver involvement or not, and intervention delivered individually or in groups of patients. Participants were asked to evaluate and compare their preferences (utilities) towards the different attribute levels within scenarios and select the pair of attribute levels that they consider to be furthest apart. RESULTS: Eighty-seven patients with lung cancer participated. The most important preferences for an intervention included the location (being delivered at home) and delivered by a health care professional. The least important preference was the involvement of a caregiver. Gender had an effect on preferences, with females being less inclined than men to prefer to receive an intervention in the home than the hospital and less inclined than men to have no other patients present. Furthermore, older participants and those in advanced stages of their disease were less inclined to have no other patients present compared to younger participants and those with earlier stages of disease, respectively. CONCLUSION: Considering patient preferences is an important step in developing feasible, patient-centred, appropriate and methodologically rigorous interventions and this study provided indications of such patient preferences.
Authors: H-Y Kim; C F Hanrahan; D W Dowdy; N A Martinson; J E Golub; J F P Bridges Journal: Int J Tuberc Lung Dis Date: 2020-04-01 Impact factor: 2.373
Authors: David M Meads; John L O'Dwyer; Claire T Hulme; Phani Chintakayala; Karen Vinall-Collier; Michael I Bennett Journal: Patient Date: 2017-10 Impact factor: 3.883
Authors: Janelle Yorke; Mari Lloyd-Williams; Jacky Smith; Fiona Blackhall; Amelie Harle; June Warden; Jackie Ellis; Mark Pilling; Jemma Haines; Karen Luker; Alex Molassiotis Journal: Support Care Cancer Date: 2015-06-26 Impact factor: 3.603
Authors: Kei Long Cheung; Ben F M Wijnen; Ilene L Hollin; Ellen M Janssen; John F Bridges; Silvia M A A Evers; Mickael Hiligsmann Journal: Pharmacoeconomics Date: 2016-12 Impact factor: 4.981
Authors: Hae-Young Kim; David W Dowdy; Neil A Martinson; Jonathan E Golub; John F P Bridges; Colleen F Hanrahan Journal: J Int AIDS Soc Date: 2018-07 Impact factor: 5.396
Authors: Thomas I Mackie; Katherine M Kovacs; Cassandra Simmel; Stephen Crystal; Sheree Neese-Todd; Ayse Akincigil Journal: Health Serv Res Date: 2020-12-28 Impact factor: 3.402